WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ real-world data program grows to sample size of nearly one million lives worldwide
20 August 2018
Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
16 April 2018
Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration
12 April 2018
Bristol-Myers Squibb's Opdivo® (nivolumab) now the first and only FDA-approved PD-1 inhibitor to offer every four-week dosing
07 March 2018
Bristol-Myers Squibb announces expansion of the International Immuno-Oncology Network (II-ON) with addition of Yale Cancer Center
01 March 2018
Bristol-Myers Squibb and Nektar Therapeutics announce global development & commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214
15 February 2018
Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk'
05 December 2017
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics
28 November 2017
BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation
10 November 2017
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review
17 October 2017
Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals
04 October 2017
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
22 September 2017
Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology
14 September 2017
Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
07 September 2017
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer
06 September 2017
Bristol-Myers Squibb announces topline results from CheckMate -214
15 August 2017
Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity
03 August 2017
Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration
31 July 2017
U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma
24 July 2017
Bristol-Myers Squibb to sell manufacturing facility in Swords, Ireland to SK Biotek Co., Ltd.
16 June 2017
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
GSK completes acquisition of Sierra Oncology
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
Research & Development
Researchers discover new leukemia-killing compounds
Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
Biomarkers found that could be drug targets against a deadly form of brain cancer
COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
Novel drug combo activates natural killer cell immunity to destroy cancer cells
Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
A new technology offers treatment for HIV infection through a single injection
Conferences & Events
New approach to treatment of deadly kidney cancer
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
SMi's 22nd Annual Pain Therapeutics Conference
SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
SMi's 3rd Annual AI in Drug Discovery Conference
Regulatory Affairs
FDA approves first systemic treatment for alopecia areata
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
FDA limits use of Janssen COVID-19 vaccine to certain individuals
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
FDA approves first generic of Symbicort to treat asthma and COPD
You are here:
Home
Bristol-Myers Squibb